Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.45 |
| ▸ | RELA | Q04206 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 2/20 | 0.39 |
| ▸ | NOS1 | P29475 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isopropyl Alcohol SCHEMBL29109553 | 0.82 | ALDH1A1 (0.50) | NFE2L2RELALMNAMAOBTDP1 | |
| Ethane SCHEMBL2154274 | 0.82 | TDP1 (0.57) | NFE2L2RELALMNAMAOBTDP1 | |
| SCHEMBL97422 | 0.82 | — | — | |
| SCHEMBL29815450 | 0.82 | — | — | |
| SCHEMBL1509673 | 0.82 | TDP1 (0.63) | NFE2L2RELALMNATDP1MEN1 | |
| SCHEMBL6918730 | 0.81 | LMNA (0.40) | NFE2L2RELALMNAMAOBTDP1 | |
| Methyl Alcohol SCHEMBL28778721 | 0.80 | TDP1 (0.55) | NFE2L2RELALMNAMAOBTDP1 | |
| Hydrochloric Acid SCHEMBL10816378 | 0.80 | TDP1 (0.60) | NFE2L2RELALMNATDP1MEN1 | |
| SCHEMBL29684596 | 0.80 | TDP1 (0.60) | NFE2L2RELALMNATDP1MEN1 | |
| SCHEMBL29924187 | 0.80 | TDP1 (0.60) | NFE2L2RELALMNATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9260406-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2016-02-16 | — | — | US | disclosed |
| EP-1976509-B1 | PPAR MODULATORS | EVOLVA SA (CH) | 2014-12-17 | — | — | EP | disclosed |
| CN-101657099-B | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA | 2014-11-26 | — | — | CN | disclosed |
| US-20140288110-A1 | PPAR MODULATORS | EVOLVA SA (CH) | 2014-09-25 | — | — | US | disclosed |
| US-20130267561-A1 | Substituted 1,3-Dioxanes Useful as PPAR Modulators | EVOLVA SA (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8536196-B2 | Substituted 1,3-dioxanes useful as PPAR modulators | EVOLVA SA (CH) | 2013-09-17 | — | — | US | disclosed |
| EP-2363127-A1 | PPAR Modulators | Evolva SA (CH) | 2011-09-07 | — | — | EP | disclosed |
| US-20110178112-A1 | PPAR Modulators | EVOLVA SA (CH) | 2011-07-21 | — | — | US | disclosed |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2010-07-01 | — | — | US | disclosed |
| CN-101657099-A | As 1 of the replacement of PPAR conditioning agent, 3-dioxane | EVOLVA SA CH | 2010-02-24 | — | — | CN | disclosed |
| EP-2150111-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | Evolva SA (CH) | 2010-02-10 | — | — | EP | disclosed |
| EP-1976509-A2 | PPAR MODULATORS | Evolva SA (CH) | 2008-10-08 | — | — | EP | disclosed |
| WO-2008089461-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | EVOLVA SA (CH) | 2008-07-24 | — | — | WO | disclosed |
| WO-2007138485-A2 | PPAR MODULATORS | EVOLVA SA (US) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178112-A1 | PPAR Modulators | PPARD, PPARG, PPARA | NFE2L2 495/4885RELA 1000/4885LMNA 3708/4885 |
| US-20140288110-A1 | PPAR MODULATORS | PPARD, PPARG, PPARA | NFE2L2 495/4885RELA 1000/4885LMNA 3708/4885 |
| US-20100168169-A1 | SUBSTITUTED 1,3-DIOXANES USEFUL AS PPAR MODULATORS | PPARD, PPARG, PPARA | NFE2L2 501/4885RELA 725/4885LMNA 2910/4885 |
| US-20130267561-A1 | Substituted 1,3-Dioxanes Useful as PPAR Modulators | PPARD, PPARG, PPARA | NFE2L2 501/4885RELA 725/4885LMNA 2910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.